Brace Yourselves for the Libertarian Tech Bro Takeover of the FDA

Two of Peter Thiel’s Silicon Valley cronies appear to be among Trump’s top choices for agency head.

<a href="http://www.istockphoto.com/photo/child-with-stomach-pain-gm468502327-34696976?st=_p_food%20poisoning">vitapix</a>/iStock

For indispensable reporting on the coronavirus crisis, the election, and more, subscribe to the Mother Jones Daily newsletter.


President-elect Donald Trump is taking his time choosing a nominee for secretary of the US Department of Agriculture—it’s the last open Cabinet post. But the USDA isn’t the only federal agency that lacks a proposed incoming leader just a week ahead of Inauguration Day. And while candidates for the USDA post have streamed thorough Trump Tower and Mar-a-Lago to plead their case, the Trump team has revealed little about whom it’s considering to head the Food and Drug Administration.

O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said. 

Until Thursday. Stat News reports that two Silicon Valley titans, Jim O’Neill and Balaji Srinivasan, met with Trump on January 12 to “discuss running the agency.” Neither are medical doctors or scientists—the typical backgrounds for most previous FDA commissioners. Rather, they’re tech guru-investors who espouse virulently libertarian views, including disdain for the FDA’s role in regulating the pharmaceutical industry.

O’Neill is a managing director of Mithril Capital, an investment firm founded by Peter Thiel, himself a hyperlibertarian investor and an early supporter of Trump’s candidacy. In a 2014 speech before a biotechnology group, O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said. 

Srinivasan, co-founder of the bitcoin startup 21.co and a partner at the venture capital firm at Andreessen Horowitz, has opined that information technology makes the FDA role in drug regulation obsolete:

Srinivasan, too, is associated with Thiel, who is an investor in Srinivasan’s bitcoin firm.

Neither Srinivasan nor O’Neill has said much publicly about the FDA’s other policy portfolio: overseeing food safety, including recently enacted rules designed to push the meat industry to rely less on antibiotics necessary for human medicine.

Trump himself has been opaque on the question of food safety regulations—though back in September, his campaign website did post, and quickly remove, a “fact sheet” denouncing the “FDA food police.”

DOES IT FEEL LIKE POLITICS IS AT A BREAKING POINT?

Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

We Recommend

Latest